



26<sup>TH</sup> EADV CONGRESS  
13 -17 SEPTEMBER 2017  
PALEXPO  
GENEVA, SWITZERLAND  
[www.eadvgeneva2017.org](http://www.eadvgeneva2017.org)

E-POSTERS  
ONLINE SUPPLEMENT

- P0165 Autoimmune progesterone dermatitis**  
 Álvarez Salafranca M. (Zaragoza, Spain), Rivera Rodríguez Á., Prieto Torres L., Abadías-Granado I., Sánchez-Bernal J., Martín Marco R., Yus Gotor C., Ara Martín M.
- P0166 Flagellate dermatitis by shiitake mushrooms: A case report**  
 Braga Oliveira L. (Rio de Janeiro, Brazil), Lins Paranhos D., Vasconcelos Barata M., Daltro A., Addario Gomes T., Leroy A.
- P0168 A 4-year analysis of patients with allergic contact dermatitis to metals in a single centre of Dermatovenereology**  
 Serpytiene E. (Vilnius, Lithuania), Grigaitiene J., Bylaite-Bucinskiene M.
- P0169 Many faces of lichen planus**  
 Jerkovic Gulin S. (Sibenik, Croatia), Chiriac A., Foia L., Chiriac A.
- P0170 Occupational irritant contact dermatitis caused by propolis**  
 Jerkovic Gulin S. (Sibenik, Croatia), Chiriac A., Birsan C., Chiriac A.
- P0171 Adverse cutaneous drug reactions to antiepileptic drugs: A 18-year experience of a tertiary referral dermatology clinic**  
 Özkaya E. (Istanbul, Turkey), Kilic S.
- P0172 One stone two targets – an autoimmune surprise!**  
 Srinivasan S. (Chennai, Tamilnadu, India)
- P0173 Erythroderma: What Lies Beneath ?**  
 Banodkar P. (Mumbai, India)
- P0174 Immunology behind the granuloma ec filler**  
 Harlim A. (Jakarta, Indonesia)
- P0175 Isotretinoin induced allergic contact dermatitis**  
 Simsek M. (Istanbul, Turkey), Karadag A., Uzuncakmak T., Ozkanlı S., Cebeci Kahraman F., Akdeniz N.
- P0176 Probiotic Supplementation Improves Urticaria Activity and Quality of Life Scores in Patients with Chronic Spontaneous Urticaria: A prospective case control study**  
 Kiziltac U. (Istanbul, Turkey), Singer R., Memet B., Kızıltac K., Yuksel E., Özdemir Ö., Kocaturk E.
- P0177 Panniculitis associated with rheumatic diseases**  
 Egorova O. (Moscow, Russian Federation)
- P0179 phytocontact dermatitis due to mentha rotundifolia: A case report**  
 El-Anzi O. (Khemisset, Morocco), Safae M., Hafsa B., Badr Eddine H.
- P0181 Harmful effects of pollen exposure on skin physiology**  
 Nora R. (Melville, United States)
- P0182 Fixed Drug Eruption: When the number of incriminated drugs exceeds lesions**  
 Ladhari C. (Tunis-Bab Souika, Tunisia), Ahmed Z., Imen A., Talel B., Ons C., Imen H., Riadh D., Sarrah K., Sihem E., Ghozlane L.
- P0183 Positive patch test to doxycycline for exploring maculopapular rash**  
 Ladhari C. (Tunis-Bab Souika, Tunisia), Ahmed Z., Imen A., Talel B., Ons C., Imen H., Riadh D., Sihem E., Sarrah K., Ghozlane L.
- P0184 Hypersensitivity to rutin confirmed by a positive patch test**  
 Ladhari C. (Tunis-Bab Souika, Tunisia), Ahmed Z., Imen A., Talel B., Ons C., Imen H., Riadh D., Sihem E., Sarrah K., Ghozlane L.
- P0185 Omalizumab for treatment urticaria in clinical practice**  
 Lesiak A. (Łódź, Poland), Bednarski I., Woźniacka A., Narbutt J.
- P0186 Multiple hypersensitivity reactions even to sampling needles**  
 Ladhari C. (Tunis-Bab Souika, Tunisia), Ahmed Z., Imen A., Talel B., Ons C., Imen H., Riadh D., Sihem E., Ghozlane L., Sarrah K.
- P0187 Interest of late reading skin testing to confirm a delayed hypersensitivity reaction to beta-lactams**  
 Ladhari C. (Tunis-Bab Souika, Tunisia), Ahmed Z., Imen A., Talel B., Ons C., Imen H., Riadh D., Sihem E., Sarrah K., Ghozlane L.



# Committees

## Executive Committee

**PAUL Carle** (FR)  
President  
**STRATIGOS Alexander** (GR)  
President-Elect  
**BORRADORI Luca** (CH)  
Past President  
**MARINOVIC Branka** (HR)  
Secretary General  
**IOANNIDES Dimitrios** (GR)  
Treasurer  
**SALAVASTRU Carmen** (RO)  
Representative of the

## Communication Committee

**RICHARD Marie-Aleth** (FR)  
Chairperson  
**BOGDANOV Ivan** (BG)  
**MURRELL Dedee** (AU)  
**RODRÍGUEZ-CERDEIRA Carmen** (ES)  
**SKERLEV Mihael** (HR)  
**SUPPA Mariano** (BE)

## EADV School

**TRAKATELLI Myrto Georgia** (GR)  
Chairperson  
**JASAITIENE Daiva** (LT)  
**PASQUALI Paola** (ES)  
**STILET Predrag** (ME)  
**VAN MONTFRANS Catherine** (NL)  
**WALSH Sarah** (UK)  
**SISKOU Styliani** (GR)  
Co-opted Junior  
**ROSSI Elena** (IT)  
Co-opted

## Ethics Committee

**SALAVASTRU Carmen** (RO)  
Chairperson  
**MIJUSKOVIC Zeljko** (RS)  
**MILINKOVIC Mirjana** (RS)  
**WAUGH Michael** (UK)  
Co-opted  
**HÖNIGSMANN Herbert** (AT)  
Invited guest



Representative of the Board  
**SZEPIETOWSKI Jacek** (PL)  
Representative of the Board

## Finance Committee

**DE RIE Menno** (NL)  
Chairperson  
**CAUX Frederic** (FR)  
**HERNANDEZ Angela** (ES)  
**LESIAK Aleksandra** (PL)  
**TIPLICA George-Sorin** (RO)  
**NEUMANN Martino** (NL)  
Invited guest

## Honours and Awards Committee

**NIKOLIĆ Miloš** (RS)  
Chairperson  
**LALLAS Aimilios** (GR)  
**NICOLAIDOU Electra** (GR)  
**BOFFA Michael** (MT)  
Co-opted  
**MERCIECA Liam** (MT)  
Co-opted Junior

## Nomination and Election Monitoring Committee

**NEUMANN Martino** (NL)  
Chairperson  
**SOUVATZIDIS Pantelis** (GR)  
**MARINOVIC Branka** (HR)  
ex officio  
**CHERNYSHOV Pavel** (UA)  
Co-opted  
**NIKOLIĆ Miloš** (RS)

## Project Proposal Review Committee

**SZEPIETOWSKI Jacek** (PL)  
Chairperson  
**DEL MARMOL Veronique** (BE)  
**SCHMIDT Enno** (DE)  
**SZEGEDI Andrea** (HU)  
**TZELLOS**



**JEADV Editor**

RING Johannes (DE)

**EADV News Editor**

ZOUBOULIS Christos (DE)

**Patient Association Working Group**

VAN MONTFRANS Catherine (NL) Chairperson  
DELEURAN Mette (DK)  
OSTENDORF Rolf (DE)  
HERCOGOVA Jana (CZ)  
DE CUYPER Christa (BE) Co-opted  
AUSTIN Jennifer (CA) Co-opted

**Nurse Association Working Group**

DE CUYPER Christa (BE) Chairperson  
NIKKELS Arjen (NL)  
ROGERS Sarah (IE)  
RYAN Sheila (IE)  
VAN MONTFRANS Catherine (NL) Co-opted  
DEPREZ Eifje (BE) Co-opted  
PENZER-HICK Rebecca (UK) Co-opted



(NL) Invited guest

Co-opted Junior

NIKOLIĆ Miloš (RS) Co-opted

TZELLOS Thrasylvoulos (NO)  
BAHADORAN Philippe (FR) co-opted

**Scientific Programming Committee**

DRÉNO Brigitte (FR) Chairperson  
ARENBERGEROVA Monika (CZ) Representing the Eastern region  
NAGORE Eduardo (ES) Representing the Southern region  
GILLIET Michel (CH) Representing the

**Statutes and Development Committee**

HOHL Daniel (CH) Chairperson  
KATOULIS Alexander (GR)  
REICH Irmingard (DE)  
ROGERS Sarah (IE)  
MANOLACHE Liana (RO)

**Task Force Facilitator**

DE CUYPER Christa (BE)

**EADV-UEMS Observer**

SALAVASTRU Carmen (RO)



European Academy of  
Dermatology and Venereology

LOGIN

BECOME A MEMBER

MENU



**Bertrand Richert**  
Belgium

**Lidia Rudnicka**  
Poland

**Ditte Marie Saunte**  
Denmark

**Erjona Shehu**  
Albania

**Bardur Sigurgeirsson**  
Iceland

**Mihael Skerlev**  
Croatia

**Markus Starink**  
Netherlands

**Predrag Stilet**  
Montenegro

**Danka Svecova**  
Slovakia

**Andrea Szegedi**  
Hungary

**Thrasylvoulos Tzellos**  
Norway

**Vladimir Vasku**  
Czech Republic



European Academy of  
Dermatology and Venereology

LOGIN

BECOME A MEMBER

MENU



**Paulo Lamarão**  
Portugal



**Antti Lauerma**  
Finland



**Elizabeth Lazaridou**  
Greece

**Aleksandra Lesiak**  
Poland

**Rémi Maghia**  
France

**Grisha Mateev**  
Bulgaria



**Željko Mijušković**  
Serbia

**Dedee Murrell**  
(International)

**Eduardo Nagore**  
Spain

**Rolf Ostendorf**  
Germany

**John Paoli**  
Sweden

**Catalin Mihai Popescu**  
Romania

**Asja Prohic**  
Bosnia and Herzegovina

**Gudrun Ratzinger**  
Austria

**Marie-Aleth Richard**  
France



Branka Marinovic

Secretary  
General

Croatia

Treasurer



Dimitrios  
Ioannides

Treasurer

Greece

Representatives of the Board

Carmen  
Salavastru

Representative of  
the Board

Romania



Jacek  
Szepietowski

Representative of  
the Board

Poland

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue without cookies

Continue with cookies

To learn more about cookies please [read here](#), or take a look at our [Privacy Policy](#)

## EADV Board members



Erkan Alpsoy  
Turkey

Elena Araviiskaia  
Russian Federation



Johann Bauer  
Austria



Can Baykal  
Turkey



Helen Borg  
Malta

Christopher Bunker  
United Kingdom

Pavel Chernyshov  
Ukraine



Michael Cork  
United Kingdom



Rodica Cosgarea  
Romania

## Leadership



**Carle Paul**  
**President**  
France



**Alexander Stratigos**  
**President-Elect**  
Greece



**Luca Borradori**  
**Past President**  
Switzerland



**All Past Presidents**  
Discover the leaders who made our history

### Secretary General



**Mateja Dolenc-Voljc**  
Slovenia



**Menno Gaastra**  
Netherlands

**Yolanda Gilaberte**  
Spain



**Michel Gilliet**  
Switzerland



**Paolo Gisondi**  
Italy

**Petter Gjersvik**  
Norway



**Margarida Gonçalo**  
Portugal



**Jan Gutermuth**  
Belgium



**Robert Hunger**  
Switzerland



**Daiva Jasaitiene**  
Lithuania



**Raimonds Karls**  
Latvia



**Alexander Katoulis**  
Greece



**Pille Konno**  
Estonia



**Paschalis Konstantinou**  
Cyprus



**Mary Laing**  
Ireland

# 26<sup>TH</sup> EADV CONGRESS

EUROPEAN ACADEMY  
OF DERMATOLOGY AND VENERELOGY

13-17 SEPTEMBER 2017  
GENEVA, SWITZERLAND

## CERTIFICATE OF PRESENTING AUTHORS

---

THIS IS TO CERTIFY THAT

**PD Dr. Dr. Ago Harlim**

PRESENTED THE FOLLOWING ABSTRACT AT THE  
26<sup>TH</sup> CONGRESS OF THE  
EUROPEAN ACADEMY OF DERMATOLOGY AND VENERELOGY

HELD IN

GENEVA, SWITZERLAND, 13-17 SEPTEMBER 2017

WITH THE TITLE

**immunology behind the granuloma ec filler**

CO-AUTHOR(S)



A handwritten signature in black ink, appearing to read 'Luca Borradori'.

PROF. LUCA BORRADORI  
EADV PRESIDENT




# Immunology Behind the Granuloma in a Case of Acne Ago Harlim

Department of Dermatology, Christian University of Indonesia

## INTRODUCTION

All injected fillers may cause foreign body granuloma in some patients. Filler which has irregular surface and can't be phagocytized may eventually form foreign body granuloma. Some of our patients with acrophages. Microspheres in the filler may be low in diameter and may be transported to local lymph node. Larger microspheres are encapsulated with fibrous tissue and may escape from phagocytosis, may cause granuloma



## METHODS

We measure the immunology of the patient with granuloma silicone injection. We measure the inflammation cytokines such as TNF- $\alpha$ , IFN- $\gamma$ , and interleukin (IL) 10. We took the blood from the patient and did the biopsy of the granuloma tissue from the injection site, to subcutaneous skin tissue surrounding the injection site.

## CONCLUSIONS

This study showed, the cytokines which produced by the macrophages and IDO in the granuloma tolerance play the role of granuloma formation due to silicone injection.

## REFERENCES

1. Sakaguchi S, Sakaguchi N, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell*. 2008;133:775-87. Mortier C, Golsbayan D. CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. *Swiss Med Wkly*. 2007;137:625-34.
2. Vellor A, Ummann D. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol*. 2004;4(10):762-74.
3. Ullmann N, Huber P, Chiroleau F, Herve L, D'Amico G. Treatment results of the program in acceptance mediated by CD8+CD45RC<sup>low</sup>T cells, IFN- $\gamma$ , and indoleamine 2,3-dioxygenase. *Int J Invest Dermatol*. 2007;17(4):1096-106.
4. Abbas K, Lichtman H, Pillai S. *Immunology*. Philadelphia: Elsevier; 2015. h. 1-12.
5. Abbas K, Lichtman A, Pillai S. Immunology: a practical approach. Oxford: Blackwell Academic; 2015. h. 315-38.
6. Curti A, Tabanelli S, Di Stefano M, Baccarani M, Romoli M. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on dermatology. *Int J Dermatol*. 2009;48(11):1239-40.
7. Jiang C, Zhang H, Wang L, Wang L. Indoleamine 2,3-dioxygenase: tissue distribution and cellular localization and its implications for biological functions. *Int J Dermatol*. 2010;49(1):17-28.

## RESULTS (CLICK TO EDIT)

Cytokine level of TNF- $\alpha$ , IFN- $\gamma$ , IL-10, IDO in supernatant blood culture PHA, RPMI silicone between normal patient group and granuloma patient group

Cytokines	Culture	Cytokines level in normal group n=37	Cytokines level in granuloma group n=31	P value
TNF- $\alpha$	PHA	757.5 (246-1327.3)	2689.6 (295-7573.6)	p=0.056*
	RPMI	91.6 (21.9-1253.8)	185.1 (23.5-1469.4)	p=0.021**
	Silicone	74.022.8 (37.0)	127.1 (8.1-2910.45)	p=0.100**
IFN- $\gamma$	PHA	372.4 (271-5283.7)	6888.3 (125.8-1372.5)	p=0.075**
	RPMI	84.5 (6.6-864.9)	175.4 (9-5329.45)	p=0.304**
	Silicone	37.83 (5.1-1275.8)	169.40 (21.3-1021.5)	p=0.310**
IL-10	PHA	191.6 (10.2-927)	192.9 (13.6-890.4)	p=0.392**
	RPMI	23.1 (8.6-112.6)	17.6 (6.5-418.5)	p=0.207**
	Silicone	22.4 (8.6-117.4)	17.13 (6.1-339.9)	p=0.281**
IDO	PHA	112.7 (92.1-7146.7)	979.4 (106.7-7366.7)	p=0.449**
	RPMI	784.2 (92.1-6280)	488.2 (97-6440)	p=0.049**
	Silicone	73.3 (166.7-5106.7)	471.5 (100.6-5600)	p=0.049**
Ratio	PHA	7.6 (0.332)	10.7 (1.609)	p=0.055**
	RPMI	3.8 (0.3279)	10.6 (0.2-63)	p=0.002**
	Silicone	4.1 (0.7254)	6.7 (0.3-51.1)	p=0.011**
TNF- $\alpha$ /IFN- $\gamma$	PHA	0.7 (0-5.9)	3.2 (0.0-14.5)	p=0.008**
	RPMI	0.1 (0-5.2)	0.3 (0-12.0)	p=0.008**
	Silicone	0.1 (0-7.0)	0.17 (0-12.2)	p=0.024**

Notes: PHA = phytohemagglutinin; RPMI = culture using *Roswell Park Memorial Institute medium*; normal serum; Silicone = industrial silicone %  
\* Mann-Whitney test; \*\* equal; n = number of patients; p = p-value  
All the data show a median number (minimum-maximum)  
\* meaningful in P < 0.05; \*\* very meaningful in P < 0.005

In this study, we looked at the blood and measured the inflammatory cytokines (TNF- $\alpha$ , IFN- $\gamma$ ) and interleukin (IL-10) in granuloma tissue and tolerance cytokines (IDO). From this study, we can see the granuloma group have higher inflammation response, but lower immune tolerance. In the granuloma, we develop to some one have high inflammation immune response but don't have tolerance immune tolerance.

Immunohistochemistry examination between granuloma tissue/clin and surrounded skin/subcutaneous skin

Variable	TNF- $\alpha$	IFN- $\gamma$	IL-10	IDO	Treg
SURROUND	p=0.596*	p=0.292*	p=0.707*	p=0.741*	p=0.616*
	r=-0.099	r=0.196	r=-0.070	r=-0.062	r=0.094
	p=0.691*	p=0.333*	p=0.611*	p=0.333*	p=0.400*
SKIN	p=0.001	p=0.074	p=0.095	p=0.180	p=0.024
	p=0.541*	p=0.816*	p=0.021*	p=0.506*	p=0.777*
	r=-0.114	r=0.044	r=0.412	r=0.124	r=-0.053
IDO	p=0.009**	p=0.003**	p=0.012**	p=0.026**	p=0.598*
	r=-0.460	r=-0.512	r=0.445	r=0.399	r=0.098
	R <sup>2</sup> =0.211	R <sup>2</sup> =0.262	R <sup>2</sup> =0.199	R <sup>2</sup> =0.160	
Treg	p=0.838*	p=0.567*	p=0.293*	p=0.034*	p=0.598*
	r=-0.038	r=0.168	r=0.195	r=-0.381	r=0.098
	R <sup>2</sup> =0.145	R <sup>2</sup> =0.145	R <sup>2</sup> =0.145	R <sup>2</sup> =0.145	

Note: \* Spearman test; \*\* meaningful in P < 0.05; \*\*\* meaningful in P < 0.005 correlation power (p 0.00-0.199 very weak, 0.20-0.399 weak, 0.40-0.599 medium, 0.60-0.799 strong, 0.80-1.00 very strong, R<sup>2</sup> = Determination coefficient

We also did the biopsy of the granuloma tissue and the skin surrounding the granuloma. And then we stained the tissue with immunohistochemistry. This is stable, you can see the inflammation cytokines (IL-10) and immune tolerance (IDO) and regulatory cytokines (IDO) surrounding the granuloma. Inflammation cytokines appear only in the granuloma tissue and the inflammation in granuloma tissue surrounding skin. In the means, our body is something for protection, trying to lock the inflammation and the inflammation cytokines. Immune tolerance is to make the inflammation not spread anywhere. This means, immune tolerance play a role in foreign body reaction and the fillers in the patient with the granuloma.

# **IMMUNOLOGY BEHIND THE GRANULOMA ec FILLER**

**Ago Harlim**

**Universitas Kristen indonesia**

## **1. BACKGROUND**

Silicone injection for cosmetics and surgery is still widely practiced in Indonesia. The result of Indonesian Association of Plastic Surgeons survey start from 2004 to 2007, found 249 cases of silicone complications.<sup>1</sup> Epidemiological data in other countries was not clear because silicone injection had been banned. In 1990, more than 100,000 patients in United States had received silicone injection in their face.<sup>3</sup> In Indonesia, there had been no research on silicone injection and its complications, although the cases were abundant. The use of silicone injection for cosmetic treatment had been banned by Federal Food, Drug & Cosmetic America (FDA) since 1992.<sup>3</sup> Liquid silicone which was injected into the skin can migrate and cause morphological changes and uncontrolled inflammatory response. Liquid silicone in the tissue is persistent, so it will lead to chronic inflammation and granulomas formation, if severe, it could be followed by infection, necrosis, and abscess.<sup>2-4</sup> Silicone granuloma is difficult to evacuate and is still able to form new granuloma after the evacuation. Immune response of granuloma is mediated by T cells, Th1 secreted pro inflammatory cytokines and Th2 secreted anti inflammatory cytokines.<sup>18</sup> The new theory of immune tolerance played by Tregs (CD4+CD25+) and Indoleamine-2,3-dioxygenase enzyme might be explained obviously the pathogenesis of granuloma formation due to silicone injection.<sup>21-24</sup> Until now, the pathogenesis of silicone granuloma has been studied, but the result are still controversial. The aimed of this study is to analyse the pathogenesis of silicone granuloma in respect to immune inflammatory response and tolerance.

## **2. METHOD OF STUDY**

Descriptive analytic method was conducted in this study, which included: (1). Cross-sectional study, to compare immune response in three groups, namely the chin granuloma tissue, submental skin and skin tissue from healthy individuals (control), and to assess the clinical correlation, histopathological, and immune responses. Samples were 31 cases of silicone

granulomas tissue and submental skin, and 37 normal skin tissue. All tissues were examined histopathologically (HE staining) to see the degree of foreign body reaction (FBR) and immunohistochemistry to assess the expression of TNF- $\alpha$ , IFN- $\gamma$ , IL-10, IDO, and Treg cells CD4<sup>+</sup>CD25<sup>+</sup>; (2). Laboratory experimental performed to assess blood cytokine levels with: (a) Culturing whole blood cells from granuloma patient and normal individuals, using RPMI medium, RPMI stimulated by PHA, and stimulated by 3% of silicone industry. (b) Examined cytokine levels from cell culture supernatant on day 3, included TNF- $\alpha$ , IFN- $\gamma$ , and IL-10. All analyzed with Luminex and IDO with ELISA. The research was conducted in specialist clinics, Faculty of Mathematics and Sciences University of Indonesia, Faculty of Medicine University of Indonesia, Faculty of Medicine Airlangga University, and Eijkman Institute, start from November 2012 until September 2014.

### **3. RESULT AND DISCUSSION**

Generally, patients with silicone injections in their chin were injected in the salon. They came for treatment approximately 12.5 years after injection, shape of chin changed in 4<sup>th</sup> years, the color of the skin changed in 5<sup>th</sup> years. Nose and chin were main area of silicone injections, 54.8% of patients with silicone injection complications were not know that the injected substance was liquid silicone. Silicone was also present in normal skin with statistical mean 44,07 $\mu$ g/g, while the silicone level in the submental skin (944  $\mu$ g/g) was significantly higher than the silicone level in the granuloma (688  $\mu$ g/g).

There was no significantly difference in the levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-10 and IDO from blood cultures stimulated by 3% of liquid silicone compared with negative control. Differences seen significantly between negative control and the positive control (PHA), ( $p < 0.001$ ).

There was significantly difference in the expression of TNF- $\alpha$ , IFN- $\gamma$ , IL-10 and IDO on inflammatory cells surface in normal skin compared with granuloma or submental skin of granuloma ( $p < 0.001$ ). However, there was no significantly difference between granuloma and submental skin of granuloma. In contrast, There was no significantly difference in Tregs population between granuloma and normal skin, but there was significantly difference between normal skin and submental skin of granuloma ( $p < 0.001$ ).

Histopathological features (with HE staining) of normal skin tissue showed that giant cells and fibrosis area was not found. Histopathologic features of granuloma showed that granuloma tissue more inflammatory than submental skin of granuloma tissue.

**Correlation between immune response in chin granuloma due to silicone injections, submental skin and blood.**

Based on a significant correlation between the expression of cytokines TNF- $\alpha$ , IFN- $\gamma$ , IL-10 and IDO on inflammatory cell surface in chin granuloma, submental skin of granuloma and normal skin with cytokines levels in blood, thus the **minor hypothesis 1**.

**Correlation between immune response in chin granuloma due to silicone injections with submental skin.**

Based on the correlation between the expression of cytokines TNF- $\alpha$ , IFN- $\gamma$ , IL-10 and immune tolerance (Treg cells (CD4+CD25+), IDO in chin granuloma and submental skin of granuloma, **minor hypothesis point 2 was accepted**.

1. There was a significant correlation between histopathologic features of granulomas with submental skin of granuloma ( $p=0.004$ ,  $r=0.507$ ), due to silicone spreading, thus the foreign body reaction also occurred in the submental skin of granuloma (Table 2).
2. Anti inflammatory cytokines in submental skin of granuloma were significantly correlated with cytokines level in granulomas tissue. Level of IL-10 in submental skin of granuloma correlated significantly with IL-10 in granuloma tissue ( $p=0.021$ ,  $r=0.412$ ), IDO in submental skin of granuloma significantly correlated with almost all cytokines (TNF- $\alpha$   $p=0.009$ ,  $r=0.460$ ; IFN- $\gamma$   $p=0.003$   $r=0.512$ ; IL-10  $p=0.012$ ;  $r=0.445$ ; IDO  $p=0.026$   $r=0.399$ ). Population of Treg cells in submental skin of granuloma was significantly correlated with the expression of IDO on inflammatory cell surface in granuloma ( $p=0.034$ ,  $r=0.381$ ) (Table 3). Based on these results, the submental skin of granuloma occurs immune tolerance to prevent damage due to inflammation by silicone.

**Histopathological features of chin granulomas and submental skin of granuloma related with period of injection, silicone levels and the degree of clinical severity**

Based on correlation of histopathological features of chin granulomas and submental skin with period of injection, silicone levels and clinical severity, so the **hypothesis minor 3 points 2, 3, 4 are accepted.**

1. Clinical severity was not associated with and silicone levels in patient with chin granuloma caused by silicone. The degree of clinical severity was not determined by period of silicone injection or silicone level, but by individual immune response.
2. Histopathologic features with three phases of granuloma significantly associated with clinical severity ( $p=0,020_{ch^*}$ ). When clinical features became more severe, histopathological features tends to be fibrosis ( $r=0.456$ ,  $p=0,010_{s^*}$ ,  $R_2=0.207$ ) (Figure 4)
3. Histopathological features with eight stages of granuloma significantly associated with period of silicone injection in granuloma tissue ( $p = 0.020$ ), and submental skin of granuloma ( $p=0.046$ ) (Figure 5). Peak of inflammation was reached around 10-19 years after silicone injection and decreased after 19 years due to individual immune tolerance.
4. Histopathological features with eight stages of granuloma significantly associated with higher levels of silicone in submental skin of granuloma ( $p=0.047$ ), but not in the granuloma tissue. it can be seen in figure 4.10, that the inflammation increased concomitantly with silicone level in submental skin of granuloma and shifted toward fibrosis gradually when silicone started to be decreasing.<sup>20,23,27</sup> Silicone level in submental skin of granuloma was more stable than in granuloma tissue.

### **The role of pro inflammatory and anti inflammatory cytokines to the occurrence of immune tolerance in patients due to silicone injections into their chin, which is assessed in granuloma tissue, skin and blood**

Based on the correlation between Treg (CD4<sup>+</sup>CD25<sup>+</sup>) population as immune tolerance properties, expression of IDO on inflammatory cell surface in granuloma tissue and submental skin with period of silicone injection and silicon level, the **minor hypothesis 4 was accepted**, described in table 4 and 5.

Expression of IDO on inflammatory cell surface did not correlate with period of silicone injection and silicone level. Population of Treg cells did not correlate with period of silicone injection, but Treg population in granuloma tissue correlated significantly with silicone level ( $p=0.033$ ,  $r=0.383$ ), (Table 4 and 5). Each individual have a difference immune tolerance,

depend on antigen level. Silicone need plasma proteins on its surface to trigger immune responses. Phases of protein adsorption on silicone surface are dynamic process and difficult to be predicted.<sup>31</sup> Patients with chin silicone injection have delayed-type hypersensitivity (DTH) reaction which would recruit lymphocytes. Silicone captured by lymphocytes via its receptor, then lymphocytes secreted both proinflammatory and antiinflammatory cytokines, and then, in this process, Treg played a role to maintain homeostasis, thus the silicone level correlated with Treg population in granuloma tissue. <sup>27</sup>

Based on the correlation between the expression of IDO on inflammatory cell surface in granuloma tissue, submental skin of granuloma and blood with clinical and histopathologic severity, then the **minor hypothesis 5 was accepted** and can be seen in table 6.

Histopathologic features of granulomas were not associated with the expression of IDO on inflammatory cell surface in granulomas, and whole blood culture with all stimulants, but histopathologic with eight phases in submental skin of granuloma was associated significantly with the expression of IDO on inflammatory cell surface in the submental skin of granuloma ( $p=0.038$ , Table 6). Expression of IDO on inflammatory cell surface in the submental skin of granuloma correlated with almost all cytokines in granuloma tissue. It is not surprising if IDO also correlated significantly with histopathological features. IDO seems to play an important role in the submental skin of granuloma so that IDO can be used as predictive tool for immune tolerance to silicone injection.

Treg did not associate with histopathologic and clinical severity, but Treg population in submental skin of granuloma significantly associated with clinical severity ( $p=0.011$ , Table 7). **Minor hypothesis 6 is accepted**, so, Treg population in the submental skin of granuloma can be used as predictive tool for observing the immune response and clinical features.

Based on the correlation between IDO and TNF- $\alpha$  and IFN- $\gamma$ , in chin granuloma, submental skin of granuloma, as well as the blood level of cytokines, then the minor hypothesis at point seven is accepted and can be seen in Table 8.

1. Level of pro inflammatory cytokines, TNF- $\alpha$  and IFN- $\gamma$ , in whole blood culture is not associated with the expression of IDO on inflammatory cell surface in both tissues but the expression of proinflammatory cytokines, TNF- $\alpha$  and IFN- $\gamma$ , in granuloma significantly correlated with the expression of IDO in both tissues (TNF- $\alpha$ ,  $r=0.592$ ,  $p<0.001$ ; IFN- $\gamma$ ,  $r=0.603$ ,  $p<0.001$ , table 8). IDO has a primary role in submental area for controlling

inflammation from silicone-consuming macrophages with IDO secretion and helps to maintain immune tolerance, so tissue damage caused by inflammation could be prevented.<sup>32-34</sup> IDO activity can be used as predictive tool for observing immune response in granuloma.

2. Treg population did not correlate with TNF- $\alpha$  and IFN- $\gamma$  in granuloma tissue and submental skin of granuloma, also in blood plasma, as well as silicone-stimulated blood, but Treg population in granuloma inversely correlated with TNF- $\alpha$  and IFN- $\gamma$  in PHA-stimulated blood (TNF- $\alpha$ ,  $r = -0.450$ ,  $p = 0.011$ ; IFN- $\gamma$ ,  $r = -0.367$ ,  $p = 0.042$ ). Lymphocytes will be stimulated by PHA. Treg cells are subset of lymphocytes that will maintain immune tolerance in granuloma caused by silicone injection. Inverse correlation happen because Treg works as an anti inflammatory, whereas TNF- $\alpha$  and IFN- $\gamma$  are pro inflammatory cytokines.<sup>17,27</sup>

Based on the correlation between Treg population (CD4<sup>+</sup>CD25<sup>+</sup>) and IDO with ratio TNF- $\alpha$ /IL-10 and IFN- $\gamma$ /IL-10 in whole blood culture and both tissue, then minor hypothesis at point eight is accepted and described on the table 9.

1. IDO in granuloma and submental skin of granuloma did not correlate to the ratio of TNF- $\alpha$ /IL-10 and IFN- $\gamma$ /IL-10 in blood plasma and PHA-stimulated blood, as well as granuloma tissue but the IDO in granuloma significantly correlated with the ratio of TNF- $\alpha$ /IL-10 in silicone-stimulated blood and submental skin of granuloma (blood,  $r = 0.418$ ,  $p = 0.019$ ; submental skin of granuloma,  $r = -0.363$ ,  $p = 0.045$ ). Based on data, IDO activity correlated with Treg function, thus the expression of IDO on inflammatory cell surface in granuloma can predict immune responses.
2. Treg population in granuloma and submental skin did not correlate to the ratio of TNF- $\alpha$ /IL-10 and IFN- $\gamma$ /IL-10 in PHA-stimulated blood and silicone-stimulated silicone, as well as in granuloma and submental skin, but Treg population in granulomas inversely correlated with the ratio of TNF- $\alpha$ /IL-10 in blood plasma ( $r = -0.460$ ,  $p = 0.009$ ). This data prove that Treg function work through IL-10.

### **The level of cytokines ratio in blood for granuloma prediction**

By assessing and comparing the inflammation that was occurred with ability of the body to inhibit inflammation with anti inflammatory cytokines or tolerance mechanism, as played by IL-10 and IDO, the ratio of TNF- $\alpha$ /IL-10 or TNF- $\alpha$ /IDO would be more accurate to be used as predictive tool. Relationship between ratio of TNF- $\alpha$ /IL-10 and TNF- $\alpha$ /IDO with period of

silicone injection can be seen in table 10. The ratio of TNF- $\alpha$ /IL-10 in PHA-stimulated blood and blood plasma and TNF- $\alpha$ /IDO in silicone-stimulated blood and blood plasma can be used as predictive tool. Inverse correlation means that the lower the ratio, the longer onset period of granuloma.

According to the table 10, the ratio of TNF- $\alpha$ /IL-10 and TNF- $\alpha$ /IDO in blood plasma can be used as predictors of the onset period of granuloma ( $p=0.038$ ;  $p=0.028$ ). Table 1 showed the significant difference between the normal and granuloma patients. Ratio of TNF- $\alpha$ /IL-10 in blood plasma of normal patients differ significantly with granuloma patients ( $p=0.002$ ). Ratio of TNF- $\alpha$ /IDO in blood plasma of normal patients differ significantly with granuloma patients ( $p=0.008$ ).

### **The level of cytokines in tissue for granuloma prediction**

Tissue examination is required if there are any indecision in the existing examination, either physical or blood cytokine examination.

Based on the results, in table 11, there was seen some cytokines correlated with clinical features and period of silicone injection. TNF- $\alpha$  expression on inflammatory cell surface in granuloma tissue significantly correlated with clinical features and period of silicone injection, but clinically most patients do not want to do the biopsy, i.e. at chin, so the submental skin of granuloma areas should be selected to represent the immune response that was occurred.

Based on table 11, Treg and IL-10 in submental skin of granuloma can be used as predictors of immune response that would happen. In accordance with the results, table 7 showed Treg had a significant correlation with clinical severity of submental skin of granuloma, whereas IL-10 in submental skin of granuloma significantly correlated with IL-10 in the granuloma tissue.

The numerical data need to be transformed to categorical data to measure prediction by mean of multivariate logistic regression. Treg population in submental skin of granuloma were splitted into two category with a cut-off limit 0.5 based on ROC analysis between Treg with the clinical features.

Result of multivariate logistic regression analysis between clinical severity with IL-10 were obtained (IL-10  $p=0.028$  and Treg  $p=0.057$ ). It was concluded that IL-10 in submental skin of granuloma can be used as the best predictor. Based on ROC analysis between IL-10 in



submental skin of granuloma and clinical features, expression limit of IL-10 in submental skin of granuloma is 138.

The higher degree of fibrosis showed immunologically improvement, but also became a problem for patients. IL-10 is an anti inflammatory cytokine and one of the cytokines produced by Treg, in addition to TGF- $\beta$ .<sup>20,27,28</sup> TGF- $\beta$  played a role in fibrosis. If IL-10 level more than 138 in submental skin of granuloma, granuloma did not need to be evacuated, actually. Evacuation procedure can be done on cosmetic indications, and must be followed-up through a standard blood test of normal patient, if IL-10 level less than 138, the patient should be recommended to treat with anti TNF- $\alpha$  or immunomodulatory, in order to avoid granuloma formation due to remaining-silicone in tissue.

Based on these data, cut off point for prediction of granuloma was establish. The median of ratios of granuloma patients can be used as cut-off point for predicting the onset of granulomas. Cut off point ratio of TNF- $\alpha$ /IL-10=3.8 and TNF- $\alpha$ /IDO=0.1 as a lowest level. If the ratio below the cut off, so we need follow up every 6 month, if above the cut off, therapy anti TNF- $\alpha$  is needed.

#### **4. CONCLUSIONS**

1. Generally, patients with chin granuloma due to silicone injection were injected in the salon. They came for treatment approximately 12.5 years after injection, the shape of chin changed in 4<sup>th</sup> years, the color of the skin changed in 5<sup>th</sup> years.
2. Level of pro inflammatory cytokines tend to be higher in patients with granuloma due to silicone injection compared to the normal patients, while anti inflammatory cytokines levels of blood tend to be lower than normal patients. Histopathological features of granuloma caused by silicone are more inflammation, while normal skin were more fibrosis.
3. There is a significant correlation between proinflammatory cytokines TNF- $\alpha$ , in blood with TNF- $\alpha$  expression on inflammatory cell surface in granuloma tissue. Level of TNF- $\alpha$  in blood can be used as predictor to assess the immune response due to silicone injection.
4. IL-10 in submental skin of granulomas significantly correlated with cytokines in granulomas. IL-10 played a role in submental skin of granuloma and can be used as the best predictor to assess the immune response in submental skin due to silicone injection.

5. Clinical severity is significantly correlated with histopathological features of granuloma. Period of injection related with histopathologic features in granulomas and submental skin. Histopathological features in submental skin of granuloma associated with higher level of silicone.
6. TNF- $\alpha$  played a role in immune response due to inflammation in granuloma, while IL-10. Treg cells and enzyme IDO played a role in immune tolerance due to silicone injection.

## REFERENCE

1. Prasetyono TOH. Data survey kasus akibat suntikan silikon di Indonesia. PERAPI. 2007.
2. Maria imelda. Unusual beauty. Penyalahgunaan silikon ternyata masih banyak. Tersedia di: <http://beautyonwatch.wordpress.com/2009/03/20/penyalahgunaan-silikon-ternyata-masih-marak/>. Diunduh 11 Agustus 2011.
3. Peters W, Fomarsier V. Complication from injectable material used for breast augmentation. The canadian journal of plastic surgery. Autumn 2009; 17(3). Tersedia di: <http://www.ncbi.nlm.nih.gov/june/article/PMC740603>. Diunduh 16 Oktober 2010.
4. James C. Mc Kinley Jr. Woman charged indeath caused by silicone injection. New York times. Maret, 2014. Tersedia di: <http://nyti.ms/1foyd4dr>. Diunduh 18 Agustus 2014.
5. Aladiw. Radang payudara malinda karena suntik silikon [Internet].2011 [updated 2011 Jun 11;cited 2011 Jun 28]. Tersedia di:  
- <http://aladiw-us/radang-payudara-malinda-karena-suntikan-silikon/>
6. Alcon Laboratories, Inc. Liquid silikon injection. Tersedia di: [http://www.yestheyrefake.net/liquid\\_silicone\\_risks.htm](http://www.yestheyrefake.net/liquid_silicone_risks.htm). Diunduh 11 Agustus 2010.
7. Nitzan D, Yahalom R, Taicher S. Silicone granuloma of lip. Harefuah. 2004;143(5):335-8, 391.
8. Takenaka M, Tanaka M, Isobe M, Yamagichi R, Kojiro M, Sirouzu K. Angiosarcoma of the breast with silicone granuloma: A case report. Kurume Med J. 2009;56:33-7.
9. Syalendra, M. Aura Cantik Berkharisma Cahaya Mutiara [Internet]. 2008 [cited 2011 Aug 8]. Tersedia di:  
- <http://www.mariasyailendra.com/produk.html>.
10. Chen YC, Chen ML, Chui YM. A case mimicking angioedema: chin silicone granulomatous reaction spreading all over the face after receiving liquid silicone injection forty years previous. Chin Med J. 2011;124(11):1747-50.
11. James S J, Pogribna M, Miller BJ, Bolon B, Muskhelishvill L. Characterization of cellular response to silicone implants in rat: implications for foreign body carcinogenesis. Biomaterial. 1997;18(9):667-75.
12. Kumar V, Abbas AK, Fausto N, Aster JC. Acute and chronic inflamation. Dalam: Kumar V, Abbas AK, Fausto N, Aster JC, ed. Robbins and Cotran. Pathologic Basic of Disease. Edisi ke-8. Philadelphia: Saunders Elsevier Inc; 2004.h.45-77.
13. Baratawijaya KG, Rengganis I. Immunologi dasar. Edisi ke-10. Jakarta: Balai penerbit FK UI; 2010.h.257-86.
14. Cakmak O, Turkoz HK, Polat S, Serin GM, Hizal E, Tanyeri H. Histopathologic response to highly purified liquid silicone injected intradermally in rat' skin. Aesth Plast Surg. 2011;35:538-44.
15. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesth Plast Surg. 2003;27:354-66. Doi:10.1007/s00266-003-3022-1.

16. Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. *Arch Dermatol.* 2005;141(1):13–15.
17. Agutini C, Semenzato G. Biology and immunology of granuloma. Dalam: James DG, Zumla A ed. *Granulomatous disorders.* United Kindom: Cambrige press; 1999.h.3-16.
18. Bondurant S, Ernster V, Herdman R. Antinuclear antibodies and silicone breast implantts. Dalam: *Safety of Silicone Breast Implants.* Washington: The National Academy Press;1999.h.198-214.
19. Bondurant S, Ernster V, Herdman R. Immunology of silicone. Dalam: *Safety of Silicone Breast Implants.* Washington: The National Academy Press; 1999.h.179-97.
20. Baratawijaya KG, Rengganis I. Toleransi imun. Dalam: *Imunologi dasar.* Edisi ke-10. Jakarta: Balai penerbit FK UI; 2012.h.287-312.
21. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell.* 2008;133:775-87.
22. Mottet C, Golsbayan D. CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. *Swiss Med wkly.* 2007;137:625-34.
23. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. *Nat Rev Immunol.* 2004;4(10):762-74.
24. Guillonneau C, Hill M, Hubert FX, Chiffolleau E, Herve C, Li XL et al. CD40 Ig treatment results in allograft acceptance mediated by CD8+CD45RClowT cells, IFN- $\gamma$ , and indoleamine 2,3-dioxygenase. *Clin invest J.* 2007; 117(4):1096-106.
25. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. Macrophage and T cell dynamics during development and disintegration of mycobacterial granulomas. *Immunity.* 2008; 28: 271-84.
26. Zaremba J, Losy J. The levels of TNF-alpha in cerebrospinal fluid and serum do not correlate with counts of the white blood cells in acute phase of ischaemic stroke. *Folia Morphol.* 2001; 60(2): 91-7.
27. Abbas AK, Lichtman AH, Pillai S. Immunological tolerance and autoimmunity. Dalam: *Cellular and molecular immunology.* Philadelphia: Saunders Elsevier Inc; 2015.h.315-38.
28. Rifa'i M. Perkembangan Sel T Regulator periferal dan mekanisme supresi *in vitro.* *J Exp life Sci.* 2010;1:1.
29. Kresno SB. *Imunologi: Diagnosis dan Prosedur Laboratorium.* Edisi ke-5. Jakarta: Balai Penerbit FKUI. 2010.h.50-97.
30. Wick G, Grundtman C, Mayerl C, Wimpissinger T, Feichtinger J, Zelger B, et al. The immunology of fibrosis. *Annu. Rev. Immunol.* 2013; 31: 107-35.
31. Zhang J M, Xiong J. Cytokines, inflammation and pain. *Int Anesthesiol Clin.* 2007;45(2):27-37.
32. Opitz CA et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl -D-tryptophan upregulates IDO1 in human cancer cells. *PLoS ONE.*2011;6(5):e19823. DOI:10.1371/journal.pone.0019823.
33. Romani L, Fallarino F, Luca AD, Montagnoli C, D'Angelo C, Zelante T, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. *Nature.* 2008 ;451:211-5.
34. Luft T, Maraskovsky E, Schnurr M. IDO production, adaptive immunity, and CTL killing. *Blood.* 2005;106:2228-9.
35. Lu Y, Giver CR, Sharma A, LI JM, Darlak KA, Owen LM, Roback JD, Galipeau J, Waller EK. IFN- $\gamma$  and indoleamine 2,3-dioxygenase signalig between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. *Blood.* 2012;119(4):1075-85.